Introduction {#cam41298-sec-0001}
============

Rectal cancer is one of the most commonly diagnosed and deadliest cancers around the world [1](#cam41298-bib-0001){ref-type="ref"}. Patients with locally advanced rectal cancer (LARC) are at tremendous risk of metastatic diseases due to high rates of local and distant recurrence [2](#cam41298-bib-0002){ref-type="ref"}. In recent years, neoadjuvant chemoradiotherapy (nCRT) has proven its efficacy in tumor downstaging and local control [3](#cam41298-bib-0003){ref-type="ref"}, [4](#cam41298-bib-0004){ref-type="ref"}. Tumor downstaging, usually indicated by the endpoint of pathologic complete response (pCR) which is defined as the complete remission of tumor cells in the resected specimen, can increase the success of radical surgery, provide better opportunity for sphincter preservation, and may be associated with increased benefit from adjuvant therapy for LARC patients [4](#cam41298-bib-0004){ref-type="ref"}, [5](#cam41298-bib-0005){ref-type="ref"}, [6](#cam41298-bib-0006){ref-type="ref"}. Thus, nCRT followed by total mesorectal excision (TME) and adjuvant chemotherapy has been highly recommended in the National Comprehensive Cancer Network (NCCN) guidelines as a standard treatment for LARC patients [7](#cam41298-bib-0007){ref-type="ref"}. However, the pCR rates reported in many studies investigating the efficacy of nCRT are far from satisfying. The FFCD trial [8](#cam41298-bib-0008){ref-type="ref"} showed a pCR rate of merely 11.4% for 375 patients in the nCRT arm, while only 13.7% of enrolled patients receiving nCRT reached pCR in the EORTC 22921 trial [9](#cam41298-bib-0009){ref-type="ref"}. pCR rates in other studies were also reported to be around 15% after the conduction of nCRT, indicating that improved nCRT regimens are necessary [10](#cam41298-bib-0010){ref-type="ref"}, [11](#cam41298-bib-0011){ref-type="ref"}, [12](#cam41298-bib-0012){ref-type="ref"}.

In the past decade, numerous emerging strategies for adding various targeted agents to nCRT regimens gained attention from oncologists. Targeted vascular endothelial growth factor (VEGF) inhibitors or epidermal growth factor receptor (EGFR) monoclonal antibodies such as bevacizumab, aflibercept, cetuximab, and panitumumab have been demonstrated to increase pCR rates and improve prognoses for metastatic colorectal cancer (mCRC) patients [13](#cam41298-bib-0013){ref-type="ref"}, [14](#cam41298-bib-0014){ref-type="ref"}, [15](#cam41298-bib-0015){ref-type="ref"}, [16](#cam41298-bib-0016){ref-type="ref"}. However, the NCCN recommends against the addition of bevacizumab, cetuximab, or panitumumab to nCRT regimens for resectable mCRC patients due to the higher incidences of wound‐healing complications, treatment‐related mortality, and reduced progression‐free survival (PFS) [7](#cam41298-bib-0007){ref-type="ref"}, [17](#cam41298-bib-0017){ref-type="ref"}, [18](#cam41298-bib-0018){ref-type="ref"}, [19](#cam41298-bib-0019){ref-type="ref"}, [20](#cam41298-bib-0020){ref-type="ref"}. On the contrary, targeted agents are recommended to be added to nCRT for unresectable mCRC patients despite the blurred standards for regimens [7](#cam41298-bib-0007){ref-type="ref"}.

In recent years, the efficacy of adding targeted agents to neoadjuvant therapies for LARC patients has been studied by abundant phase II trials, with pCR being the primary endpoint [21](#cam41298-bib-0021){ref-type="ref"}, [22](#cam41298-bib-0022){ref-type="ref"}, [23](#cam41298-bib-0023){ref-type="ref"}, [24](#cam41298-bib-0024){ref-type="ref"}. Yet, with few randomized controlled trials (RCTs) or clinical controlled trials (CCTs) available, we lack head‐to‐head data of time‐to‐event endpoints such as overall survival (OS) and PFS to evaluate the survival status of LARC patients receiving targeted agents in their nCRT regimens compared with those receiving nCRT alone. Thus, we focused on the pCR rates of LARC patients to study the efficacy of adding targeted agents to their neoadjuvant therapies. pCR has become a widely accepted prognostic indicator in LARC patients [25](#cam41298-bib-0025){ref-type="ref"}. Maas et al. [26](#cam41298-bib-0026){ref-type="ref"}. conducted a meta‐analysis of a large amount of individual patient data provided by 14 investigators and concluded that rectal cancer patients with pCR have better local control, a lower rate of distant recurrence, and improved survival compared to those without pCR. Several other investigations have also recommended pCR as an indicator of better outcome concerning local or distant recurrence, disease‐free survival (DFS), and OS [27](#cam41298-bib-0027){ref-type="ref"}, [28](#cam41298-bib-0028){ref-type="ref"}, [29](#cam41298-bib-0029){ref-type="ref"}, [30](#cam41298-bib-0030){ref-type="ref"}, [31](#cam41298-bib-0031){ref-type="ref"}. However, the reported pCR rates in the current studies vary, ranging from approximately 39.1% [32](#cam41298-bib-0032){ref-type="ref"} to merely 4.3% [33](#cam41298-bib-0033){ref-type="ref"}. The sample sizes of these studies are also relatively small, the largest being 83[34](#cam41298-bib-0034){ref-type="ref"} and the smallest consisting of only eight patients [35](#cam41298-bib-0035){ref-type="ref"}. Therefore, the efficacy of adding targeted agents to the nCRT for LARC patients is still controversial.

Since pCR shows promise as a prognosis indicator, in this meta‐analysis we pooled the data of pCR rates extracted from the included studies to evaluate whether adding targeted agents to neoadjuvant therapies improves the outcome of LARC patients.

Methods {#cam41298-sec-0002}
=======

Study selection {#cam41298-sec-0003}
---------------

This meta‐analysis was conducted following the Preferred Reporting Items for Systematic Reviews and Meta‐analysis (PRISMA) statements checklist [36](#cam41298-bib-0036){ref-type="ref"}.

The predefined criteria for eligible studies were as follow: (1) Patients with locally advanced rectal cancer (cT3‐4 primary rectal cancer and/or lymph node metastasis, without evidence of distant metastatic diseases). (2) Application of approved targeted agents in neoadjuvant therapy. (3) Endpoint of interest was pCR. (4) Original studies only (case reports, reviews, pooled‐analyses, and letters to the editor were excluded). Phase I clinical trials, which aim to evaluate the safety of novel agents, were also ruled out. (5) If investigations presented overlapping cohorts, studies which were more recently published and of higher quality were chosen.

Search strategy {#cam41298-sec-0004}
---------------

PubMed, Embase, and Web of Science were searched using a combination of the following terms: "rectal," "rectum," "colorectal," "tumor," "cancer," "neoplasm," "neoadjuvant," "preoperative," "perioperative," "targeted," "VEGF," "EGFR," "bevacizumab," "cetuximab," "C225," "panitumumab," "ramucirumab," and "aflibercept" for relevant publications up to December 17, 2016. The references of the relevant studies were also screened for potential pertinent articles. There were no language restrictions used during the search.

Data extraction {#cam41298-sec-0005}
---------------

The primary endpoint was pCR and the second endpoint was the proportion of patients who encountered any Grade 3/4 toxic effects during preoperative chemoradiotherapy (preoperative Grade 3/4 toxicity). Data were manually extracted by two independent reviewers (X Zhong and Z.H. Wu) using standardized sheets. Any discrepancies between them were resolved by a third senior author.

The baseline details of the included studies were extracted by the same two reviewers and listed in the sheets mentioned above, and all the data entries were reviewed by the third senior author. The following data were extracted from VEGF‐inhibitor‐relevant studies: author and year of publication, study design, enrollment, regimen of neoadjuvant therapy, median age, tumor staging of included patients at enrollment, and the distance of primary tumor from anal verge. The following data were extracted from EGFR‐inhibitor‐relevant studies: author and year of publication, study design, enrollment, regimen of neoadjuvant therapy, median age, tumor staging of included patients at enrollment, the distance of primary tumor from anal verge, and KRAS status. The Newcastle‐Ottawa quality assessment scale (NOS) was applied to assess the quality of eligible studies for meta‐analysis [37](#cam41298-bib-0037){ref-type="ref"}. Studies which scored five or more were considered as moderate‐quality trials, whereas those with seven or more were regarded as high‐quality trials.

Statistical analysis {#cam41298-sec-0006}
--------------------

All statistical analyses were performed using STATA version 12.0 (STATA, College Station, TX). Meta‐analyses were conducted by calculating the pooled estimates of pCR and preoperative Grade 3/4 toxicity, and a random‐effect model was used which provides more conservative estimates for the inevitable heterogeneity of included multicenter studies [38](#cam41298-bib-0038){ref-type="ref"}. To evaluate heterogeneity, the Cochrane\'s *Q* test and inconsistent index (I^2^) were performed, with I^2^ \< 40% considered acceptable [19](#cam41298-bib-0019){ref-type="ref"}, [39](#cam41298-bib-0039){ref-type="ref"}, [40](#cam41298-bib-0040){ref-type="ref"}. Potential origins of heterogeneity were detected by performing sensitivity analysis. Publication biases were evaluated via funnel plots, Begg\'s funnel plot, and Egger linear regression test for further confirmation [19](#cam41298-bib-0019){ref-type="ref"}.

Results {#cam41298-sec-0007}
=======

Study selection and the characteristics of included studies {#cam41298-sec-0008}
-----------------------------------------------------------

We identified 804 publications through the initial database search and screening the references of relevant studies, and 788 remained after removing duplicates. We excluded 740 records after reading their titles and abstracts, leaving 48 potentially eligible studies for full‐text review. A total of 32 studies were ultimately included, after ruling out 16 ineligible investigations which failed to meet the inclusion and exclusion criteria for this meta‐analysis. The included studies consisted of 21 for the VEGF inhibitor, bevacizumab [21](#cam41298-bib-0021){ref-type="ref"}, [22](#cam41298-bib-0022){ref-type="ref"}, [23](#cam41298-bib-0023){ref-type="ref"}, [32](#cam41298-bib-0032){ref-type="ref"}, [33](#cam41298-bib-0033){ref-type="ref"}, [35](#cam41298-bib-0035){ref-type="ref"}, [41](#cam41298-bib-0041){ref-type="ref"}, [42](#cam41298-bib-0042){ref-type="ref"}, [43](#cam41298-bib-0043){ref-type="ref"}, [44](#cam41298-bib-0044){ref-type="ref"}, [45](#cam41298-bib-0045){ref-type="ref"}, [46](#cam41298-bib-0046){ref-type="ref"}, [47](#cam41298-bib-0047){ref-type="ref"}, [48](#cam41298-bib-0048){ref-type="ref"}, [49](#cam41298-bib-0049){ref-type="ref"}, [50](#cam41298-bib-0050){ref-type="ref"}, [51](#cam41298-bib-0051){ref-type="ref"}, [52](#cam41298-bib-0052){ref-type="ref"}, [53](#cam41298-bib-0053){ref-type="ref"}, [54](#cam41298-bib-0054){ref-type="ref"}, [55](#cam41298-bib-0055){ref-type="ref"}, and 11 for EGFR inhibitors (eight for cetuximab [34](#cam41298-bib-0034){ref-type="ref"}, [56](#cam41298-bib-0056){ref-type="ref"}, [57](#cam41298-bib-0057){ref-type="ref"}, [58](#cam41298-bib-0058){ref-type="ref"}, [59](#cam41298-bib-0059){ref-type="ref"}, [60](#cam41298-bib-0060){ref-type="ref"}, [61](#cam41298-bib-0061){ref-type="ref"}, [62](#cam41298-bib-0062){ref-type="ref"}, one for nimotuzumab [63](#cam41298-bib-0063){ref-type="ref"} and two for panitumumab [64](#cam41298-bib-0064){ref-type="ref"}, [65](#cam41298-bib-0065){ref-type="ref"}). These included one randomized clinical trial (RCT) [54](#cam41298-bib-0054){ref-type="ref"} and three clinical controlled trials (CCT) [34](#cam41298-bib-0034){ref-type="ref"}, [53](#cam41298-bib-0053){ref-type="ref"}, [55](#cam41298-bib-0055){ref-type="ref"}, but we only analyzed cohorts which tested the addition of targeted agents to their neoadjuvant therapy regimens for this meta‐analysis. There were also two bevacizumab‐relevant studies [22](#cam41298-bib-0022){ref-type="ref"}, [52](#cam41298-bib-0052){ref-type="ref"} consisting of two arms with bevacizumab in their neoadjuvant regimens, and we included all four cohorts for the meta‐analysis. Additionally, there was one study [49](#cam41298-bib-0049){ref-type="ref"} consisting of two cohorts testing addition of bevacizumab, one in the neoadjuvant setting and the other in the postoperative setting, and we included only the former. The rest of the remaining studies were all single‐arm investigations. After the search, we determined that there were inadequate nimotuzumab‐relevant and panitumumab‐relevant studies to conduct a meta‐analysis. Thus, a total of 1196 subjects from 31 cohorts of 29 studies were eligible for quantitative synthesis. The whole selection process is presented in a flow diagram (Fig. [1](#cam41298-fig-0001){ref-type="fig"}). The baseline characteristics and data regarding the primary and secondary endpoints of the included studies for meta‐analysis are shown in Table [1](#cam41298-tbl-0001){ref-type="table-wrap"} (bevacizumab‐relevant studies) and Table [2](#cam41298-tbl-0002){ref-type="table-wrap"} (cetuximab‐relevant studies). The NOS quality assessment of the included investigations for meta‐analysis is shown in Table [3](#cam41298-tbl-0003){ref-type="table-wrap"}. Among the 29 studies, three scored seven points and were regarded as high‐quality studies and the remaining 26 all scored six points and were considered as studies of moderate quality.

![Selection of studies. Flow diagram showing the selection process for the included studies.](CAM4-7-565-g001){#cam41298-fig-0001}

###### 

Baseline characteristics of cohort groups of bevacizumab for meta‐analysis

  Study                   Study design                Enrollment, *n*   Neoadjuvant therapy                                 Median age, year              Stage at enrollment, *n*                                                                                       Distance from anal verge, cm   PreoperativeGrade3/4 toxicity   pCR
  ----------------------- --------------------------- ----------------- --------------------------------------------------- ----------------------------- -------------------------------------------------------------------------------------------------------------- ------------------------------ ------------------------------- ---------------
  Blaszkowsky 2014        Prospective Phase I/II      32                5‐FU + Erlotinib + bevacizumab + RT                 NR                            cT3N0: 6; cT3N1: 15; cT3N2: 4; cT3Nx: 4; cT4N0: 2; cT4N1: 1                                                    NR                             46.9% (15/32)                   33.3% (9/27)
  Borg 2014               Prospective Phase II        46                Folfox‐4 + bevacizumab                              60.6                          cT3N0: 10; cT3N1: 31; Tc3N2: 5                                                                                 NR                             50% (23/46)                     23.8% (10/42)
  45                      5‐FU + bevacizumab + RT     60.1              cT3N0: 8; cT3N1: 28; cT3N2: 9                       NR                            20% (9/45)                                                                                                     11.4% (5/44)                                                   
  Crane 2010              Prospective Phase II        25                Capecitabine + bevacizumab + RT                     54.0                          cT3N0: 5; cT3N0+: 20                                                                                           ≤5 cm: 15; \>5 cm: 10          NR                              32% (8/25)
  Dellas 2013             Prospective Phase II        69                Capox + bevacizumab + RT                            61.0                          cT2Nx: 2; cT3N0: 12; cT3N0 + : 44; cT4N0: 3; cT4N+: 4:                                                         5.92 ± 3.68 (Mean ± SD)        11.6% (8/69)                    17.4% (12/69)
  Dipetrillo2012          Prospective Phase II        25                mFOLFOX6 + bevacizumab + RT                         50.0                          T2: 2; T3: 20; T4: 3; N‐: 7; N+: 16; Nx: 2                                                                     NR                             76% (19/25)                     20% (5/25)
  Fernandez‐Martos 2014   Prospective Phase II        46                Capox + bevacizumab                                 NR                            cT3: 46                                                                                                        NR                             NR                              19.6% (9/46)
  Garcia 2015             Prospective Phase II        41                Capecitabine + bevacizumab + RT                     63.0                          cT3[a](#cam41298-note-0004){ref-type="fn"}: 32; cT3a: 3; cT3b: 1; cT3c: 2; cT4: 2                              NR                             7.3% (3/41)                     7.5% (3/40)
  Gasparini 2012          Prospective Phase II        43                Capecitabine + bevacizumab + RT                     64.0                          cT2N1M0: 4; cT3N0M0: 14; cT3N1M0: 20; cT3NxM0: 1; cT4N1M0: 1; cT4N1M0: 1; cT4N2M0: 1; cTxN1M0: 1; cT4N2M1: 1   NR                             NR                              14.0%(6/43)
  Hasegawa 2014           Prospective Pilot study     25                Capox + bevacizumab                                 63.0                          cT4aN0M0: 1; cT4bN0M0: 3; cT2,cT3N2M0: 3; cT3,cT4aN1M0: 10; cT4aN2M0: 1; cT4bN1/N2M0: 7                        5.0 (Median)                   28% (7/25)                      4.3% (1/23)
  Landry 2015             Prospective Phase II        54                Capox + bevacizumab + RT                            54.0                          cT3: 50; cT4: 4; cNx: 2; cN0: 17; cN1: 30; cN2: 5                                                              NR                             NR                              17.0% (9/53)
  Nogue 2011              Prospective Phase II        47                Capox + bevacizumab + RT                            58.5                          cT3N0: 5; cT3N1: 22; cT3N2: 14; cT4N0: 2; cT4N1: 2; cT4N2: 2                                                   NR                             NR                              35.6% (16/45)
  Resch 2012              Prospective Phase II        8                 Capecitabine + bevacizumab + RT                     70.0                          cT3: 8; cN0: 1; cN1: 4; cN2: 1; cNx: 2                                                                         NR                             37.5% (3/8)                     25% (2/8)
  Sadahiro 2015           Prospective Phase II        52                S‐1 + bevacizumab + RT                              59.0                          cT2: 2; cT3: 49; cT4: 1; cN0: 16; cN1: 36                                                                      5.5 (Median)                   1.9% (1/52)                     19.2% (10/52)
  Spigel 2012             Prospective Phase II        35                5‐FU + bevacizumab + RT                             57.0                          II: 11; III: 24                                                                                                NR                             NR                              28.6% (10/35)
  Uehara 2013             Prospective Phase II        32                Capox + bevacizumab                                 62.0                          cT3: 13; cT4a: 9; cT4b: 10; cN0: 6; cN1: 14; cN2: 12                                                           4.7 (Median)                   25% (8/32)                      13.3% (4/30)
  Velenik 2011            Prospective Phase II        61                Capecitabine + bevacizumab + RT                     60.0                          cT3N0: 12; cT2N1: 1; cT3N1: 19; cT2N2: 2; cT3N2: 22; cT4N2: 5                                                  6.0 (Median)                   NR                              13.3% (8/60)
  Wang 2014               Prospective Phase II        12                FOLFOX + bevacizumab + RT/5‐FU + bevacizumab + RT   52.5                          cT2: 1; cT3: 8; cT4: 3; cN0: 2; cN1: 2; cN2: 8                                                                 5 cm: 5; 5‐10 cm: 7; ≥10: 0    16.7% (2/12)                    33.3% (4/12)
  6                       FOLFOX + bevacizumab + RT   57.5              cT2: 0; cT3: 5; cT4: 1; cN0: 2; cN1: 4; cN2: 0      5 cm: 1; 5‐10 cm: 4; ≥10: 1   16.7% (1/6)                                                                                                    25% (1/4)                                                      
  Xiao 2015               Prospective Phase II        25                5‐FU + oxaliplatin + bevacizumab + RT               45.0                          cT2: 2; cT3: 9; cT4a: 8; cT4b: 6; cN‐: 4; cN+: 21                                                              ≤5 cm: 7; \>5 cm: 18           NR                              39.1% (9/23)
  Koukourakis 2011        Prospective Phase II        19                Capecitabine + bevacizumab + RT                     68.0                          pT3: 19; pT4: 0; pN1: 12                                                                                       NR                             NR                              36.8% (7/19)
  Salazar 2015            Prospective Phase II        44                Capecitabine + bevacizumab + RT                     64.0                          II A: 6; II B: 1; III B: 18; III C: 19                                                                         6.5 (Median)                   15.9% (7/44)                    15.9% (7/44)
  Willett 2010            Prospective Phase II        32                5‐FU + bevacizumab + RT                             51.0                          cT3: 28; cT4: 4; cN0: 9; cN1‐2: 23                                                                             NR                             21.9% (7/32)                    15.6% (5/32)

pCR, pathologic complete response; RT: radiotherapy; 5‐FU, fluorouracil; FOLFOX, leucovorin plus fluorouracil plus oxaliplatin; Capox, capecitabine plus oxaliplatin; S‐1, tegafur plus gimeracil plus potassium oxonate; NR, not reported.

It was not specified if the cT3 status was cT3a, cT3b or cT3c.

John Wiley & Sons, Ltd

###### 

Baseline characteristics of cohort groups of cetuximab for meta‐analysis

  Study              Study design             Enrollment   Neoadjuvant therapy                    Median age, year   Stage at enrollment                                            Distance from anal verge, cm                                                                                    KRAS status                                                         Preoperative Grade3/4 toxicity   pCR
  ------------------ ------------------------ ------------ -------------------------------------- ------------------ -------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------- -------------------------------- --------------
  Bengala 2009       Prospective Phase II     40           5‐FU + cetuximab + RT                  61                 uT3N0: 12; uT3N1: 25; uT4N1: 3                                 NR                                                                                                              Wild‐type: 30; Mutated: 9                                           NR                               7.7% (3/39)
  Horisberger 2009   Prospective Phase II     50           Capecitabine+Irinotecan+cetuximab+RT   57                 cT2: 5; T3: 42; cT4: 2; Local relapse: 1; cN0: 13; cN+: 37     7.5 (Median) (1--13, Range)                                                                                     NR                                                                  NR                               8% (4/50)
  Kim 2011           Prospective Phase II     40           CapIri + cetuximab + RT                56.5               cT3N0: 6; cT3N+: 30; cT4N0: 2; cT4N+: 2                        ≤5: 19 \> 5: 21 5.5 (Median) (0--8.0, Range)                                                                    Wild‐type: 33; Mutated: 5                                           17.9% (7/39)                     23.1% (9/39)
  Machiels 2007      Prospective Phase I/II   40           Capecitabine + cetuximab + RT          61                 cT2N+: 2; cT3N0: 18; cT3N+: 13; cT4N0: 5; cT4N+: 2             \<6 cm: 25 6--10 cm: 10 \> 10 cm: 5                                                                             NR                                                                  NR                               5% (2/40)
  Rodel 2008         Prospective Phase I/II   60           Capox + cetuximab + RT                 61.5               cT2N1‐2: 1; cT3N0: 7; cT3N1‐2: 43; cT4N0: 2; cT4N1‐2: 7        7 ± 3.5 (Mean ± SD) 0--14 (Range) Lower third (≤6 cm): 27 Middle third (6--12 cm): 27 Upper third (≥12 cm): 6   NR                                                                  NR                               8.9% (4/45)
  Sun 2012           Prospective Phase II     63           Capecitabine + cetuximab + RT          64                 cT3N0: 8; cT3N1: 21; cT3N2: 26; cT4N0: 2; cT4N1: 2; cT4N2: 4   5 (Median) (1--9, Range)                                                                                        Wild‐type: 44; Mutated: 19                                          NR                               12.7% (8/63)
  Velenik 2012       Prospective Phase II     47           Capecitabine + cetuximab + RT          55                 cT3N0: 3; cT2N1: 1; cT3N1: 13; cT2N2: 1; cT3N2: 15; cT4N2: 4   6 (Median) (1--11, Range)                                                                                       Wild‐type: 30; Mutated: 7                                           NR                               8.1% (3/37)
  Dewdney 2012       Prospective Phase II     83           Capecitabine + cetuximab + RT          61                 cT3c‐ T3d: 47; T4: 21                                          NR                                                                                                              [a](#cam41298-note-0006){ref-type="fn"}Wild‐type: 46; Mutated: 37   NR                               18% (15/83)

pCR, pathologic complete response; RT, radiotherapy; 5‐FU, fluorouracil; CapIri, capecitabine plus irinotecan; Capox, capecitabine plus oxaliplatin; NR, not reported.

KRAS/BRAF status.

John Wiley & Sons, Ltd

###### 

The NOS quality of included studies

  Study                   Selection   Comparability   Outcome   Total   Quality                       
  ----------------------- ----------- --------------- --------- ------- --------- --- --- --- --- --- ----------
  Blaszkowsky 2014        1           0               1         1       0         0   1   1   1   6   Moderate
  Borg 2014               1           1               1         1       0         0   1   1   1   7   High
  Crane 2010              1           0               1         1       0         0   1   1   1   6   Moderate
  Dellas 2013             1           0               1         1       0         0   1   1   1   6   Moderate
  Dipetrillo 2012         1           0               1         1       0         0   1   1   1   6   Moderate
  Fernandez‐Martos 2014   1           0               1         1       0         0   1   1   1   6   Moderate
  Garcia 2015             1           0               1         1       0         0   1   1   1   6   Moderate
  Gasparini 2012          1           0               1         1       0         0   1   1   1   6   Moderate
  Hasegawa 2014           1           0               1         1       0         0   1   1   1   6   Moderate
  Landry 2015             1           0               1         1       0         0   1   1   1   6   Moderate
  Nogue 2011              1           0               1         1       0         0   1   1   1   6   Moderate
  Resch 2012              1           0               1         1       0         0   1   1   1   6   Moderate
  Sadahiro 2015           1           0               1         1       0         0   1   1   1   6   Moderate
  Spigel 2012             1           0               1         1       0         0   1   1   1   6   Moderate
  Uehara 2013             1           0               1         1       0         0   1   1   1   6   Moderate
  Velenik 2011            1           0               1         1       0         0   1   1   1   6   Moderate
  Wang 2014               1           0               1         1       0         0   1   1   1   6   Moderate
  Xiao 2015               1           0               1         1       0         0   1   1   1   6   Moderate
  Koukourakis 2011        1           0               1         1       0         0   1   1   1   6   Moderate
  Salazar 2015            1           1               1         1       0         0   1   1   1   7   High
  Willett 2010            1           0               1         1       0         0   1   1   1   6   Moderate
  Bengala 2009            1           0               1         1       0         0   1   1   1   6   Moderate
  Horisberger 2009        1           0               1         1       0         0   1   1   1   6   Moderate
  Kim 2011                1           0               1         1       0         0   1   1   1   6   Moderate
  Machiels 2007           1           0               1         1       0         0   1   1   1   6   Moderate
  Rodel 2008              1           0               1         1       0         0   1   1   1   6   Moderate
  Sun 2012                1           0               1         1       0         0   1   1   1   6   Moderate
  Velenik 2012            1           0               1         1       0         0   1   1   1   6   Moderate
  Dewdney 2012            1           1               1         1       0         0   1   1   1   7   High

REC, representativeness of the exposed cohort; SNEC, selection of the nonexposed cohort; AE, ascertainment of exposure; DO, demonstration that outcome of interest was not present at start of study; SC, study controls for age, sex; AF, study controls for any additional factors; AO, assessment of outcome; FU: follow‐up long enough (36M) for outcomes to occur; AFU, adequacy of follow‐up of cohorts (≥90%). "1″ means that the study satisfies the item and "0" means the opposite situation.

John Wiley & Sons, Ltd

The efficacy and safety of VEGF inhibitor {#cam41298-sec-0009}
-----------------------------------------

The pooled estimate of pCR for bevacizumab‐relevant cohorts was 27% (95%CI, 21--34%) (Fig. [2](#cam41298-fig-0002){ref-type="fig"}A). Meanwhile, the pooled estimate of preoperative Grade 3/4 toxicity for bevacizumab‐relevant cohorts was 36% (95% CI, 20--63%) (Fig. [3](#cam41298-fig-0003){ref-type="fig"}A). To better learn about the increased risk of clinically relevant toxicities, we listed the incidences of anti‐VEGF‐relevant toxicity focusing on bleeding, gastrointestinal perforation, and wound‐healing complication (shown in Table [4](#cam41298-tbl-0004){ref-type="table-wrap"}). The pooled estimates of Grade 3/4 bleeding, Grade 3/4 gastrointestinal perforation, and Grade 3/4 wound‐healing complication were also calculated and the results were 2.1% (95% CI, 1.0--4.7%) for Grade 3/4 bleeding, 1.9% (95% CI, 0.7--5.4%) for Grade 3/4 gastrointestinal perforation and 2.4% (95% CI, 1.0--6.2%) for Grade 3/4 wound‐healing complication.

![(A) The pooled estimate of pCR for bevacizumab‐relevant cohorts. (B) The results of subgroup analysis of bevacizumab‐relevant cohorts. The pooled estimates of pCR. pCR, pathologic complete response.](CAM4-7-565-g002){#cam41298-fig-0002}

![(A) The pooled estimate of preoperative Grade 3/4 toxicity for bevacizumab‐relevant cohorts. (B) The results of subgroup analysis of bevacizumab‐relevant cohorts. The pooled estimates of preoperative Grade 3/4 toxicity.](CAM4-7-565-g003){#cam41298-fig-0003}

###### 

The treatment‐related toxicity status of patients who received additional anti‐VEGF or anti‐EGFR agents in neoadjuvant treatment

  Study                   Enrollment, n   Neoadjuvant therapy                                 Grade 3/4 treatment‐related toxicity[a](#cam41298-note-0009){ref-type="fn"}
  ----------------------- --------------- --------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------
  Blaszkowsky 2014        32              5‐FU + Erlotinib + bevacizumab + RT                 NR
  Borg 2014               46              Folfox‐4 + bevacizumab                              Grade 3/4 gastrointestinal perforation: 1/46 (2.17%)Grade 3/4 bleeding/hemorrhage: 2/46 (4.35%)Grade 3/4 wound‐healing complication: 0
                          45              5‐FU + bevacizumab + RT                             Grade 3/4 gastrointestinal perforation: 0Grade 3/4 bleeding/hemorrhage: 0Grade 3/4 wound‐healing complication: 2/45 (4.44%)
  Crane 2010              25              Capecitabine + bevacizumab + RT                     NR
  Dellas 2013             69              Capox + bevacizumab + RT                            Grade 3/4 delayed wound‐healing: 1/69 (1.45%)
  Dipetrillo2012          25              mFOLFOX6 + bevacizumab + RT                         Grade 3/4 bleeding: 1/25 (4%)
  Fernandez‐Martos 2014   46              Capox + bevacizumab                                 NR
  Garcia 2015             41              Capecitabine + bevacizumab + RT                     NR
  Gasparini 2012          43              Capecitabine + bevacizumab + RT                     Grade 3/4 rectal hemorrhage: 0
  Hasegawa 2014           25              Capox + bevacizumab                                 NR
  Landry 2015             54              Capox + bevacizumab + RT                            Grade 3/4 CNS hemorrhage: 1/54 (1.85%)
  Nogue 2011              47              Capox + bevacizumab + RT                            Grade 3/4 hemorrhage: 0
  Resch 2012              8               Capecitabine + bevacizumab + RT                     NR
  Sadahiro 2015           52              S‐1 + bevacizumab + RT                              NR
  Spigel 2012             35              5‐FU + bevacizumab + RT                             Grade 3/4 wound complication: 0
  Uehara 2013             32              Capox + bevacizumab                                 Grade 3/4 perforation: 1/32 (3.13%)
  Velenik 2011            61              Capecitabine + bevacizumab + RT                     Grade 3/4 bleeding: 10/61 (16.39%)
  Wang 2014               12              FOLFOX + bevacizumab + RT/5‐FU + bevacizumab + RT   NR
                          6               FOLFOX + bevacizumab + RT                           NR
  Xiao 2015               25              5‐FU + oxaliplatin + bevacizumab + RT               NR
  Koukourakis 2011        19              Capecitabine + bevacizumab + RT                     NR
  Salazar 2015            44              Capecitabine + bevacizumab + RT                     NR
  Willett 2010            32              5‐FU + bevacizumab + RT                             NR
  Bengala 2009            40              5‐FU + cetuximab + RT                               NR
  Horisberger 2009        50              Capecitabine + Irinotecan + cetuximab + RT          NR
  Kim, S. Y 2011          40              CapIri + cetuximab + RT                             Grade 3/4 diarrhea: 2/40 (12.5%)Grade 3/4 hand‐foot syndrome: 0Grade 3/4 skin rash: 2/40 (5%)
  Machiels 2007           40              Capecitabine + cetuximab + RT                       Grade 3/4 diarrhea: 6/40(15%);Grade 3/4 hand‐foot syndrome: 1/40 (2.5%);Grade 3/4 acneiform rash: 0
  Rodel 2008              60              Capox + cetuximab + RT                              Grade 3/4 diarrhea: 9/60 (15%)Grade 3/4 hand‐foot syndrome: 0Grade 3/4 radiation dermatitis: Grade 3: 4/60 (6.67%);Grade 3/4 acneiform rash: 2/60 (3.33%)
  Sun 2012                63              Capecitabine + cetuximab + RT                       Grade 3/4 diarrhea: 0Grade 3/4 hand and foot syndrome: 0Grade 3/4 radiodermatitis: 10/63 (15.87%)Grade 3/4 acneiform rash: 4/63 (6.35%)
  Velenik 2012            47              Capecitabine + cetuximab + RT                       Grade 3/4 diarrhea: 4/47 (8.51%)Grade 3/4 hand‐foot syndrome: 0Grade 3/4 acneiform rash: 0
  Dewdney 2012            83              Capecitabine + cetuximab + RT                       NR
  Jin 2015                21              Capecitabine + nimotuzumab + RT                     Grade 3/4 diarrhea: 2/21 (9.52%)Grade 3/4 hand‐foot skin reaction: 0Grade 3/4 radiation dermatitis: 0Grade 3/4 acneiform rash: 0
  Helbling 2013           40              Capecitabine + panitumumab + RT                     Grade 3/4 diarrhea: 4/40 (10%)Grade 3/4 hand‐foot syndrome: 1/40 (2.5%)Grade 3/4 acneiform rash: 1/40 (2.5%)
  Pinto 2011              60              5‐FU + oxaliplatin + panitumumab + RT               Grade 3/4 diarrhea: 23/60 (38.33%)Grade 3/4 hand‐foot syndrome: 0Grade 3/4 acneiform rash: 11/60 (18.33%)

RT, radiotherapy; 5‐FU, fluorouracil; FOLFOX, leucovorin plus fluorouracil plus oxaliplatin; Capox, capecitabine plus oxaliplatin; S‐1, tegafur plus gimeracil plus potassium oxonate; NR, not reported.

We focused on bleeding and bowel perforation and impaired wound‐healing for anti‐VEGF‐relevant cohorts and diarrhea and skin changes in the affected area of the skin involved in radiotherapy for anti‐EGFR‐relevant cohorts.

John Wiley & Sons, Ltd

To further evaluate the efficacy and safety of bevacizumab, we performed a subgroup analysis by separating the bevacizumab‐relevant cohorts into two subgroups: the 5‐fluorouracil‐based (5‐FU‐based) bevacizumab group and the capecitabine‐based bevacizumab group. The results of the subgroup analysis showed that the 5‐FU‐based bevacizumab group had a pooled estimate for pCR of 32% (95% CI, 23--43%) (Fig. [2](#cam41298-fig-0002){ref-type="fig"}B) and the pooled estimate of preoperative Grade 3/4 toxicity reached 42% (95% CI, 19--94%) (Fig. [3](#cam41298-fig-0003){ref-type="fig"}B). For capecitabine‐based bevacizumab group, a pooled pCR of 23% (95% CI, 17--33%) was achieved (Fig. [2](#cam41298-fig-0002){ref-type="fig"}B) along with a pooled estimate of preoperative Grade 3/4 toxicity of 25% (95% CI, 16--42%) (Fig. [3](#cam41298-fig-0003){ref-type="fig"}B).

The efficacy and safety of EGFR inhibitors {#cam41298-sec-0010}
------------------------------------------

The pooled estimate of pCR for cetuximab‐relevant studies was 14% (95% CI, 9--21%) (Fig. [4](#cam41298-fig-0004){ref-type="fig"}). One study [58](#cam41298-bib-0058){ref-type="ref"} reported a preoperative Grade 3/4 toxicity of approximately 17.9%, while the others did not report toxicity in this manner.

![The pooled estimate of pathologic complete response for cetuximab‐relevant cohorts.](CAM4-7-565-g004){#cam41298-fig-0004}

We reviewed the few studies involving the other EGFR inhibitors, although their low numbers made additional analysis unavailable. In the only study [63](#cam41298-bib-0063){ref-type="ref"} focusing on nimotuzumab, four (19%) of 21 enrolled patients achieved pCR. For the two studies studying panitumumab, one [65](#cam41298-bib-0065){ref-type="ref"} reported a pCR rate of 21.1% in 57 eligible patients and the other, a RCT [64](#cam41298-bib-0064){ref-type="ref"} showed a 10% pCR rate for patients receiving panitumumab in addition with nCRT versus 18% for patients treated with nCRT alone.

To comprehensively evaluate the increased risk of clinically relevant toxicities, we listed the incidences of anti‐EGFR‐relevant toxicity focusing on diarrhea and skin changes in the affected area of the skin involved in radiotherapy (shown in Table [4](#cam41298-tbl-0004){ref-type="table-wrap"}). The pooled estimates of Grade 3/4 diarrhea, Grade 3/4 hand‐foot syndrome, Grade 3/4 rash, and Grade 3/4 radiodermatitis were also calculated and the results were 13.3% (95% CI, 6.4--27.9%) for Grade 3/4 diarrhea, 1.5% (95% CI, 0.6--3.7%) for Grade 3/4 hand‐foot syndrome, 5.2% (95% CI, 2.2--11.9%) for Grade 3/4 rash and 10.7% (95% CI, 4.2--27.1%) for Grade 3/4 radiodermatitis.

Evaluation of publication bias {#cam41298-sec-0011}
------------------------------

To evaluate publication bias, we performed Begg\'s test and Egger\'s test. The *P* values of Begg\'s test and Egger\'s test for the pooled pCR of bevacizumab‐relevant cohorts were 0.303 and 0.277 (Fig. [S2](#cam41298-sup-0002){ref-type="supplementary-material"}). The *P* values of Begg\'s test and Egger\'s test for the pooled preoperative Grade 3/4 toxicity of bevacizumab‐relevant cohorts were 0.714 and 0.257 (Fig. [S3](#cam41298-sup-0003){ref-type="supplementary-material"}). The *P* values of Begg\'s test and Egger\'s test for the pooled pCR of cetuximab‐relevant cohorts were 0.048 and 0.005 (Fig. [S4](#cam41298-sup-0004){ref-type="supplementary-material"}). To further evaluate the potential publication bias detected from the pooled pCR of cetuximab‐relevant cohorts, we performed sensitivity analysis, the results are shown in Figure [S5](#cam41298-sup-0005){ref-type="supplementary-material"}.

Discussion {#cam41298-sec-0012}
==========

Since the use of neoadjuvant therapies began, a tremendous amount of work has been done to improve the regimens. Abundant clinical trials and two meta‐analyses have revealed the efficacy of preoperative radiotherapy granting better local control and a lower rate of local recurrence for LARC patients compared with surgery alone [66](#cam41298-bib-0066){ref-type="ref"}, [67](#cam41298-bib-0067){ref-type="ref"}. Subsequently, the addition of 5‐FU or capecitabine to neoadjuvant radiotherapy was demonstrated to significantly increase the incidence of pCR, and they have been widely accepted as first‐line anticancer regimens in the clinic [8](#cam41298-bib-0008){ref-type="ref"}, [68](#cam41298-bib-0068){ref-type="ref"}. More recently, researchers have studied the roles of various targeted agents added to the nCRT setting in pursuit of higher pCR rates for LARC patients. However, whether or not the addition of targeted agents to the nCRT regimens provides increased efficacy remains controversial and requires further investigation.

Until now, there have been limited RCTs and CCTs investigating the roles of targeted agents in nCRT regimens for LARC patients, and most of the studies in this field were single‐arm phase II studies. These single‐arm phase II studies basically focus on the pCR rates to demonstrate the efficacy of a certain targeted agent, and often lack data regarding patient survival status [35](#cam41298-bib-0035){ref-type="ref"}, [46](#cam41298-bib-0046){ref-type="ref"}, [47](#cam41298-bib-0047){ref-type="ref"}. Under these circumstances, a benchmark pCR rate would be necessary to be able to evaluate the efficacy of the additional targeted agents to the nCRT regimens. However, single‐arm phase II clinical trials lack a putative benchmark and usually evaluate the efficacy by comparing their pCR results with their predefined goal for pCR rate or the results of pCR in other studies [21](#cam41298-bib-0021){ref-type="ref"}, [22](#cam41298-bib-0022){ref-type="ref"}, [23](#cam41298-bib-0023){ref-type="ref"}. To help evaluate the efficacy of bevacizumab when added to the neoadjuvant therapy for LARC patients, we established a benchmark by quantitatively synthesizing the pCR rates of neoadjuvant therapy regimens without added targeted agents for LARC patients. We extracted pCR rates from ten cohorts that met our patient enrollment criteria and without any targeted agents in their nCRT regimens from the pooled analysis of Maas et al. [26](#cam41298-bib-0026){ref-type="ref"}. The baseline characteristics of these cohorts are shown in Table [S1](#cam41298-sup-0006){ref-type="supplementary-material"} and the pooled estimate of pCR of these cohorts was 17% (95% CI, 15--20%) (Fig. [S1](#cam41298-sup-0001){ref-type="supplementary-material"}). This benchmark is also in the range of the pCR rates reported in several other previous studies [3](#cam41298-bib-0003){ref-type="ref"}, [4](#cam41298-bib-0004){ref-type="ref"}, [8](#cam41298-bib-0008){ref-type="ref"}, [10](#cam41298-bib-0010){ref-type="ref"}, [11](#cam41298-bib-0011){ref-type="ref"}, [12](#cam41298-bib-0012){ref-type="ref"}. Therefore, we believe that 17% is an adequate benchmark that can help reasonably evaluate the efficacy of adding targeted agents to the nCRT for LARC patients.

Willett et al. [69](#cam41298-bib-0069){ref-type="ref"} were the pioneers in investigating the role of bevacizumab in 5‐FU‐based nCRT, and they achieved a feasible pCR rate of 16%. Other researchers also devoted themselves to evaluating the efficacy of bevacizumab in nCRT for LARC patients [21](#cam41298-bib-0021){ref-type="ref"}, [22](#cam41298-bib-0022){ref-type="ref"}, [23](#cam41298-bib-0023){ref-type="ref"}. In our study, we achieved a pooled pCR rate (27%) over the benchmark (17%) and thus, demonstrated an appreciable pCR for the addition of bevacizumab to neoadjuvant therapy for LARC patients. Moreover, the results of the subgroup analysis showed that the 5‐FU‐based group achieved a higher pooled estimate of pCR (32%) than capecitabine‐based group (23%), yet the pCR rates for both groups were higher than the benchmark (17%). One previous study demonstrated [70](#cam41298-bib-0070){ref-type="ref"} that capecitabine‐based nCRT was superior to 5‐FU‐based nCRT in 5‐year overall survival, 3‐year DFS, reduction in distant metastasis, and pCR rate. Alternatively, a more recent meta‐analysis comparing the efficacies of oral capecitabine and infusional 5‐FU [71](#cam41298-bib-0071){ref-type="ref"} demonstrated no significant difference between the pCR rates of the two groups in a neoadjuvant setting. The NCCN guidelines also comment that the efficacy of these two drugs is "equivalent" [7](#cam41298-bib-0007){ref-type="ref"}. In pursuit of a plausible explanation, we extracted and evaluated the RT status of bevacizumab‐relevant cohorts considering the tumor‐downsizing nature of RT (shown in Table [S2](#cam41298-sup-0007){ref-type="supplementary-material"}). Three of the 13 capecitabine‐based cohorts do not include RT in their neoadjuvant therapy while only one of the 10 5‐FU‐based cohorts does not include RT. And the pCR of two of these three capecitabine‐based cohorts are distinctly low, merely 4.3% (1/23) and 13.3% (4/30). Besides, a total of 53 individuals who did not receive RT hold over a tenth of the whole capecitabine‐based group population. These may help explain the controversial result of this subgroup analysis to some extent. In summary, bevacizumab shows appreciable efficacy in nCRT for LARC patients, and this efficacy is consistent in 5‐FU‐based nCRT and capecitabine‐based nCRT. As our enrolled studies are mostly phase II clinical trials, this efficacy can encourage more incoming phase III clinical trials and serve as evidence of a promising outlook for future clinical applications of bevacizumab in nCRT regimens for LARC patients.

It is well‐known that chemotherapy can cause toxicity in patients. Thus, it is inevitable that adding targeted agents in nCRT regimens could result in extra toxicity. Sauer et al. [4](#cam41298-bib-0004){ref-type="ref"} reported a Grade 3/4 toxicity rate of 27% in 399 rectal cancer patients receiving preoperative chemoradiotherapy. Two other important RCTs [3](#cam41298-bib-0003){ref-type="ref"}, [8](#cam41298-bib-0008){ref-type="ref"} showed that Grade 3/4 toxicity occurred in 13.9% and 14.6% of their enrolled patients, respectively, in the duration of nCRT. A previous study [72](#cam41298-bib-0072){ref-type="ref"} also demonstrated that LARC patients in two cohorts with different nCRT regimens without any targeted agents reached pCR rates of 17% and 13% at the cost of Grade 3/4 toxicities of 23% and 20%, respectively. In our study, the pooled estimates of preoperative Grade 3/4 toxicity (36% for total bevacizumab‐relevant cohorts, 42% for 5‐FU‐based bevacizumab group cohorts, and 25% for capecitabine‐based bevacizumab group cohorts) are reasonable considering the high rates of pooled pCR (27%, 32%, and 23%, respectively) in bevacizumab‐relevant cohorts. Additionally, the incidences of anti‐VEGF‐relevant toxicity listed in Table [4](#cam41298-tbl-0004){ref-type="table-wrap"} and the pooled estimates indicate that anti‐VEGF treatment‐relevant toxicities are relatively mild. Thus, we presume that the safety of bevacizumab is acceptable.

The role of cetuximab, an anti‐EGFR monoclonal antibody, in nCRT for LARC patients has been investigated by many researchers in recent years [56](#cam41298-bib-0056){ref-type="ref"}, [59](#cam41298-bib-0059){ref-type="ref"}. In our study, we found that the pooled estimate for pCR in cetuximab‐relevant cohorts is less than the benchmark, which may indicate an inadequate efficacy of adding cetuximab to the nCRT for LARC patients. Increasing evidences have demonstrated that KRAS‐mutated patients cannot benefit from anti‐EGFR treatments [34](#cam41298-bib-0034){ref-type="ref"}, [73](#cam41298-bib-0073){ref-type="ref"}, [74](#cam41298-bib-0074){ref-type="ref"}, [75](#cam41298-bib-0075){ref-type="ref"}. It is also a well‐known fact that anti‐EGFR activity might be also strictly dependent on the presence/lack of mutations in NRAS or BRAF genes [7](#cam41298-bib-0007){ref-type="ref"}, [76](#cam41298-bib-0076){ref-type="ref"}, [77](#cam41298-bib-0077){ref-type="ref"}. In our study, most of the included cetuximab‐relevant studies only focus on KRAS status and did not report their pCR rates according to the KRAS status of the enrolled patients. Thus, the inadequate pooled pCR rate of cetuximab‐relevant cohorts may be due to the lack of published mutation status. As such, additional investigations are needed to explore the efficacy of adding cetuximab to the neoadjuvant therapy specifically for RAS and BRAF wild‐type LARC patients.

The few studies [63](#cam41298-bib-0063){ref-type="ref"}, [64](#cam41298-bib-0064){ref-type="ref"}, [65](#cam41298-bib-0065){ref-type="ref"} investigating the roles of nimotuzumab and panitumumab in the nCRT for LARC patients did not show convincing evidence for efficacy or safety, so more investigations regarding nimotuzumab and panitumumab are urgently needed. Two ongoing surveys [78](#cam41298-bib-0078){ref-type="ref"}, [79](#cam41298-bib-0079){ref-type="ref"} focusing on bevacizumab and lapatinib are expected to provide more evidence on the outcome of LARC patients in a couple of years.

Despite the inadequate pCR, the addition of anti‐EGFR agents presents acceptable safety and this safety may facilitate more anti‐EGFR‐oriented clinical trials.

No publication bias was detected in the meta‐analysis for bevacizumab‐relevant cohorts. However, the results of Begg\'s and Egger\'s tests concerning the pCR for cetuximab‐relevant cohorts suggested the existence of potential publication bias. The results of sensitivity analysis, as shown in Figure [S5](#cam41298-sup-0005){ref-type="supplementary-material"}, seem to indicate that the pooled pCR of cetuximab‐relevant cohorts deviates from the current value most when Dewdney et al\'s study is omitted. Thus, we comprehensively reviewed this well‐designed RCT of Dewdney et al\'s and found that the pCR rate of their cetuximab‐relevant arm (18%) was higher than most of the other included cetuximab‐relevant cohorts. Meanwhile, this cohort held the largest weight in the quantitative analysis due to the largest sample size (83) among all of the inclusions. Besides, over half of the population (46) in this cohort are KRAS/BRAF wild type which is previously reported to present good response to anti‐EGFR treatment. All of the above accounts for the higher pCR presented in this cohort and explains why this pCR influences the pooled estimate most.

Our study is the first meta‐analysis to evaluate the efficacy of targeted agents in the nCRT for LARC patients. However, several limitations exist in our study. First, due to the lack of relevant RCTs and CCTs, we conducted this meta‐analysis in a single‐arm setting. Second, we only focused on pCR and its indicative role in our meta‐analysis and we lack data regarding perioperative and postoperative outcomes including operation time, perioperative complication rate, and postoperative recovery time so that we cannot directly evaluate the potential influences that adding targeted agents may have on the following curative surgical resection and postoperative recovery of LARC patients which highly concern clinical practitioners in this field. Third, cohort numbers from single‐arm studies included in this study are mostly small‐scale, which can lead to over‐reporting of the efficacy of these neoadjuvant regimens. Meanwhile, heterogeneity is, to an extent, inevitable among these multi‐center studies. Fourth, most of the anti‐EGFR cohorts are small‐scale and stress KRAS status only. To the best of our knowledge, however, anti‐EGFR activity might be also strictly determined by the mutational statuses of NRAS and BRAF. Fifth, when conducting this study, we only focused on published studies and extracted data available in the text, thus, we did not have access to relevant individual patient data, which could help us improve the analysis of the treatment effects of the targeted agents. Despite these limitations, we found that there is increased efficacy when adding bevacizumab to nCRT for LARC patients.

Conclusion {#cam41298-sec-0013}
==========

In conclusion, our study revealed that adding bevacizumab to the neoadjuvant therapy regimens provides an appreciable pCR for LARC patients. However, more RCTs are needed for further validation. Meanwhile, the efficacy of cetuximab remains inconclusive, RCTs with larger scale and better study design that stress more on mutational status are needed.
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**Figure S1.** The establishment of benchmark for pCR.
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**Figure S2.** (a) The Begg\'s funnel plots concerning the pCR for bevacizumab‐relevant studies. (b) The Egger\'s publication bias plot concerning the pCR for bevacizumab‐relevant studies.
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**Figure S3.** (a) The Begg\'s funnel plots concerning the preoperative Grade 3/4 toxicity for bevacizumab‐relevant studies. (b) The Egger\'s publication bias plot concerning the preoperative Grade 3/4 toxicity for bevacizumab‐relevant studies.
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**Figure S4**. (a) The Begg\'s funnel plots concerning the pCR for cetuximab‐relevant studies. (b) The Egger\'s publication bias plot concerning the pCR for cetuximab‐relevant studies.
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**Figure S5.** The results of the sensitivity analysis concerning the pCR for cetuximab‐relevant studies.
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**Table S1.** Data from Maas, et al\'s pooled analysis.
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**Table S2.** The radiotherapy status of Bevacizumab‐relevant cohorts.

###### 

Click here for additional data file.

This work was supported by Clinical Capability Construction Project for Liaoning Provincial Hospitals (LNCCC‐A01‐2014), the Key Laboratory Programme of Education Department of Liaoning Province (LZ2015076) and Scientific Programme of Science & Technology Department of Liaoning Province(2015225002).

[^1]: These authors contributed equally to this work
